Regulatory News:
(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)
As of March 31, 2012, shares and voting rights outstanding of Essilor (Paris:EI), the world leader in ophthalmic optics, broke down as follows:
| Â | Â | March 31, 2012 |
| Shares outstanding | 212,445,851 | |
| Exercisable voting rights | 223,018,345 | |
Total voting rights, based on all outstanding shares, including shares stripped of their voting rights* | 227,782,895 |
(*) Shares held by the Company, either in treasury or under the liquidity contract.
------------------------
About Essilor
The world's leading ophthalmic optics
company,Essilor designs, manufactures and markets a wide range of lenses
to improve and protect eyesight.Its corporate mission is to enable
everyone around the world to access lenses that meet his or her unique
vision requirements.To support this mission, the Company allocates
around €150 million to research and development every year, in a
commitment to continuously bring new, more effective products to
market.Essilor's flagship brands are Varilux®,
Crizal®, Definity®,
Xperio®, Optifog™ and Foster Grant®. It
also develops and markets equipment, instruments and services for
eyecare professionals.
Essilor reported consolidated revenue
of €4.2 billion in 2011 and employs nearly 48,700 people.
It
operates 19 plants, a total of 390 prescription laboratories and edging
facilities, as well as several research and development centers around
the world.
For more information, please visit www.essilor.com.
The
Essilor share trades on the NYSE Euronext Paris market and is included
in the CAC 40 index.
Codes and symbols:ISIN:FR0000121667;
Reuters:ESSI.PA; Bloomberg:EI:FP.
Contacts:
Investor Relations and Financial Communications
Phone:
+33 (0)1 49 77 42 16
